Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03208660 · ClinicalTrials.gov registry record
Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy
A clinical trial, sponsored by Eisai.
- Completed
- Registry status
- 2,000
- Enrollment target
NCT03208660: Completed study, sponsored by Eisai.
NCT03208660 is a clinical trial that has completed, run by Eisai. The registered enrollment target is 2,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03208660 has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- 2,000 participants
- Enrollment target
Study Summary
This study is conducted to assess the retention rate of Fycompa when given in routine clinical care.
Primary Outcome
Retention rate is the ratio of the number of participants remaining on Fycompa treatment to the number of participants who could have been exposed for that length of time.
Interventions
- DRUG Fycompa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2017-04-07 |
| Est. Completion | 2019-03-15 |
What the finished NCT03208660 record still lists
NCT03208660 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Fycompa is the first listed.
NCT03208660 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03208660 about?
NCT03208660 is a clinical study titled "Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy". This study is conducted to assess the retention rate of Fycompa when given in routine clinical care.
What is the current status of trial NCT03208660?
This trial is currently completed. The enrollment target is 2,000 participants. The study started on 2017-04-07. Estimated completion is 2019-03-15.
What interventions are being tested in trial NCT03208660?
The interventions under investigation include: Fycompa (DRUG).
Who is sponsoring clinical trial NCT03208660?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI